Cytokine · 2013
Polydesensitisation with reducing elevated serum total IgE by IFN-gamma therapy in atopic dermatitis: IFN-gamma and polydesensitisation (PDS).
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Jae Ho, Noh Geunwoong
Аннотация
BACKGROUND: AD patients exhibit sensitisation to multiple allergens due to a Th1/Th2 imbalance. Until now, it was impossible to improve the polysensitised status and elevated serum total IgE levels. In this study, the effects of IFN-gamma on systemic polysensitisation to multiple allergens and on serum total IgE levels are investigated.
METHODS: A total of 44 AD patients whose food allergies were completely controlled and who were polysensitised to multiple allergens according to the SPT were selected. Twenty-two of these patients received IFN-gamma therapy twice a week for 2 months, and 22 patients did not receive this therapy. The blood eosinophil % and serum total IgE levels were assessed, and a skin prick test for 51 allergens was performed before and after the IFN-gamma therapy.
RESULTS: With IFN-gamma therapy, the polysensitisation status was improved, as demonstrated by a decrease in the positive allergen count and skin reactivity (systemic polydesensitisation). The improvement in the polysensitised status was accompanied by a decrease in serum total IgE levels. The change in serum total IgE levels was significantly correlated with the change in polysensitisation status.
CONCLUSIONS: IFN-gamma therapy resulted in systemic polydesensitisation with reduced levels of serum total IgE. IFN-gamma is indicated in AD patients with high serum total IgE levels whose food allergies are well controlled and who are polysensitised to multiple allergens.
METHODS: A total of 44 AD patients whose food allergies were completely controlled and who were polysensitised to multiple allergens according to the SPT were selected. Twenty-two of these patients received IFN-gamma therapy twice a week for 2 months, and 22 patients did not receive this therapy. The blood eosinophil % and serum total IgE levels were assessed, and a skin prick test for 51 allergens was performed before and after the IFN-gamma therapy.
RESULTS: With IFN-gamma therapy, the polysensitisation status was improved, as demonstrated by a decrease in the positive allergen count and skin reactivity (systemic polydesensitisation). The improvement in the polysensitised status was accompanied by a decrease in serum total IgE levels. The change in serum total IgE levels was significantly correlated with the change in polysensitisation status.
CONCLUSIONS: IFN-gamma therapy resulted in systemic polydesensitisation with reduced levels of serum total IgE. IFN-gamma is indicated in AD patients with high serum total IgE levels whose food allergies are well controlled and who are polysensitised to multiple allergens.